These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 32180217)

  • 1. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain.
    Li S; Selkoe DJ
    J Neurochem; 2020 Sep; 154(6):583-597. PubMed ID: 32180217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.
    Yang T; Li S; Xu H; Walsh DM; Selkoe DJ
    J Neurosci; 2017 Jan; 37(1):152-163. PubMed ID: 28053038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
    Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
    Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.
    Wang Z; Jackson RJ; Hong W; Taylor WM; Corbett GT; Moreno A; Liu W; Li S; Frosch MP; Slutsky I; Young-Pearse TL; Spires-Jones TL; Walsh DM
    J Neurosci; 2017 Dec; 37(49):11947-11966. PubMed ID: 29101243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease.
    Shi XD; Sun K; Hu R; Liu XY; Hu QM; Sun XY; Yao B; Sun N; Hao JR; Wei P; Han Y; Gao C
    J Neurosci; 2016 Nov; 36(47):11959-11973. PubMed ID: 27881781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
    Laurén J; Gimbel DA; Nygaard HB; Gilbert JW; Strittmatter SM
    Nature; 2009 Feb; 457(7233):1128-32. PubMed ID: 19242475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term Potentiation
    Ondrejcak T; Klyubin I; Hu NW; O'Malley TT; Corbett GT; Winters R; Perkinton MS; Billinton A; Prenderville JA; Walsh DM; Rowan MJ
    J Neurosci; 2023 Aug; 43(32):5870-5879. PubMed ID: 37491315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.
    Balducci C; Beeg M; Stravalaci M; Bastone A; Sclip A; Biasini E; Tapella L; Colombo L; Manzoni C; Borsello T; Chiesa R; Gobbi M; Salmona M; Forloni G
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2295-300. PubMed ID: 20133875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.
    Selkoe DJ
    Behav Brain Res; 2008 Sep; 192(1):106-13. PubMed ID: 18359102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
    Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
    PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors.
    Kervern M; Angeli A; Nicole O; Léveillé F; Parent B; Villette V; Buisson A; Dutar P
    J Alzheimers Dis; 2012; 32(1):183-96. PubMed ID: 22785392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers.
    Townsend M; Shankar GM; Mehta T; Walsh DM; Selkoe DJ
    J Physiol; 2006 Apr; 572(Pt 2):477-92. PubMed ID: 16469784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct types of amyloid-β oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease.
    Madhu P; Mukhopadhyay S
    J Cell Biochem; 2021 Nov; 122(11):1594-1608. PubMed ID: 34494298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.
    Shankar GM; Li S; Mehta TH; Garcia-Munoz A; Shepardson NE; Smith I; Brett FM; Farrell MA; Rowan MJ; Lemere CA; Regan CM; Walsh DM; Sabatini BL; Selkoe DJ
    Nat Med; 2008 Aug; 14(8):837-42. PubMed ID: 18568035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.
    Hu NW; Klyubin I; Anwyl R; Rowan MJ
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20504-9. PubMed ID: 19918059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies.
    Rowan MJ; Klyubin I; Wang Q; Anwyl R
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):563-7. PubMed ID: 16042545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities.
    Li S; Stern AM
    Mol Psychiatry; 2022 Aug; 27(8):3182-3191. PubMed ID: 35484241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.